Raynaud’s Phenomenon after Combined Adjuvant Chemotherapy for Breast Cancer

Accessible online at: www.karger.com/che Raynaud’s phenomenon (RP) is classified as primary disease if no other associated disease can be found and as secondary if an underlying disorder has been detected upon assessment [1]. In recent years, antineoplastic chemotherapeutic agents are among the factors linked with an increased incidence of RP. We describe a patient in whom RP developed after four cycles of combined chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil (CMF).